print_label | resize_label

Zoladex® (goserelin)

PRIOR TO PRESCRIBING, PLEASE REFER TO THE SmPC FOR FULL PRODUCT INFORMATION. THIS CAN BE FOUND IN THE BOX ON THE RIGHT, TOGETHER WITH THE PATIENT INFORMATION LEAFLET.

Zoladex packshot

Description

Zoladex® is a Lutenising Hormone-Releasing Hormone analogue (LHRHa)

Formulations

Zoladex® is available as a 3.6 mg implant and a 10.8 mg implant in a pre-filled syringe.

Indication

Zoladex® 3.6mg is indicated for prostate cancer suitable for hormonal manipulation, advanced breast cancer in pre- and peri-menopausal women suitable for hormonal manipulation, the management of endometriosis and the pre-thinning of uterine endometrium.

Zoladex® 10.8 mg is indicated for prostate cancer suitable for hormonal manipulation.

For full details of the licensed indications please refer to the Summary of Product Characteristics via the links under Further Information

Administration Video

Watch the video showing how to administer the Zoladex® (goserelin) injection

This content is not currently available for your device.

X


Job bag number: GB-4473

Date of preparation: December 2016

Page Options

Page Options

Average Rating

Edit Rating

Thank you

Edit Rating

Print

Section Favourites

Adverse events

AstraZeneca Medical Information